Skip to main content
SpringerLink
Log in

Assessing cardiovascular safety of febuxostat in gout

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities, supported by Takeda Development Center Americas

Reference

  • White WB, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. New England Journal of Medicine : 12 Mar 2018. Available from: URL: http://doi.org/10.1056/NEJMoa1710895

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Assessing cardiovascular safety of febuxostat in gout. Reactions Weekly 1694, 6 (2018). https://doi.org/10.1007/s40278-018-43408-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-43408-z

Search

Navigation